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Human complement is a first line defense against
infection in which circulating proteins initiate an
enzyme cascade on the microbial surface that leads
to phagocytosis and lysis. Various pathogens evade
complement recognition by binding to regulator
proteins that protect host cells from complement
activation. We show that emerging gametes of the
malaria parasite Plasmodium falciparum bind the
host complement regulator factor H (FH) following
transmission to the mosquito to protect from
complement-mediated lysis by the blood meal.
Human complement is active in the mosquito
midgut for approximately 1 hr postfeeding. During
this period, the gamete surface protein PfGAP50
binds to FH and uses surface-bound FH to inactivate
the complement protein C3b. Loss of FH-mediated
protection, either through neutralization of FH or
blockade of PfGAP50, significantly impairs gameto-
genesis and inhibits parasite transmission to the
mosquito. Thus, Plasmodium co-opts the protective
host protein FH to evade complement-mediated lysis
within the mosquito midgut.
INTRODUCTION
The human complement is an important part of innate immunity.
One of its major features is the recognition and destruction of
invading microbes through the formation of a terminal complex
to induce targeted lysis. Particularly, the alternative pathway of
complement (APC) plays a key role during microbe infections
since it is activated continuously at a low rate by spontaneous
hydrolysis of complement factor C3 and thus functions as
a ‘‘watchdog’’ of the innate immune system. C3b, a product of
C3 hydrolysis, attaches covalently to the microbe surface and
triggers APC activation. In order to prevent any damage of self
cells by the APC, human cells use a variety of complement
regulators. These include factor H (FH), one of the mostCell Habundant plasma proteins in the human body (reviewed in
Pangburn, 2000; Rodrı´guez de Co´rdoba et al., 2004; Zipfel and
Skerka, 2009).
FH is a 155 kDa protein comprising 20 complement control
protein (CCP) modules. FH regulates alternative complement
activation by dissociating the C3 convertase C3bBb (decay
accelerating activity) and mediating degradation of C3b to the
inactive form iC3b by factor I (cofactor activity). An alternative
splicing product of FH, FH-like protein (FHL-1), comprises CCP
modules 1–7 and can also regulate APC activity. Additionally,
the FH family includes the five complement FH-related (CFHR)
proteins 1–5, which show overall homologies to CCP modules
6 and 7 and CCP modules 19 and 20 (reviewed in Skerka and
Zipfel, 2008; Jo´zsi and Zipfel, 2008, Zipfel et al., 2008).
In the course of pathogen-host coevolution, numerous human
pathogenic microbes have developed strategies to inhibit or
control complement recognition (reviewed in Zipfel et al.,
2007). A common strategy of microbial pathogens during
immune evasion is to bind human complement regulator
proteins, thereby mimicking host cell surfaces. For several of
these microbes, like Streptococcus pneumoniae, Borrelia burg-
dorferi, or Candida albicans, receptor proteins have been identi-
fied that mediate the binding of regulators, and the immune
evasion mechanisms have been studied extensively (reviewed
in Zipfel et al., 2007). However, complement evasion mecha-
nisms hitherto are not well described for human parasites and
not known for Plasmodium parasites, the causative agents of
the tropical disease malaria.
Malaria is amajor health burden, causing 216million infections
and approximately 655,000 deaths annually (World Malaria
Report, 2011).Malaria infections can persist for weeks ormonths
in the infected individuals, during which time the parasites repli-
cate in the human red blood cells. The compartmentalization of
Plasmodium inside the erythrocytes is a means by which the
parasites can evade the host immune system, including the
human complement. Once malaria parasites enter the sexual
pathway, though, they have to exit the protecting erythrocyte
in order to form gametes and prepare for fertilization.
The sexual pathway of the malaria parasite starts with the
formation of sexual precursor cells, the intraerythrocytic game-
tocytes (GCs), which are taken up by the mosquito. Triggered
by external stimuli of the mosquito midgut, the activated GCsost & Microbe 13, 29–41, January 16, 2013 ª2013 Elsevier Inc. 29
AB
C
E
D
F
gametocytes post-act.
Figure 1. Activity of Human Complement in the Mosquito Blood Meal and Binding of FH to Activated GCs
(A) C3a concentration in the bloodmeal ofAn. stephensiwith or without prior treatment ofmosquitoes with gentamicin, asmeasured by ELISA. The optical density
(450 nm) of the PBS control was set to 1 (represented as mean ± SD). */**/***, significant increase in C3a (*p < 0.05, **p < 0.01, ***p < 0.001; Student’s t test).
(B) Numbers of exflagellation centers at 15min p.a., macrogametes at 20min p.a., and zygotes at 20 hr p.a. after GC activation with NHS or HIS in the absence or
presence of anti-FHmAb 131X. The number of NHS-activated cells was set to 100% (represented as mean ± SD). Significant differences in parasite numbers are
indicated (*p < 0.05; Student’s t test).
(legend continued on next page)
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Protection of Malaria Parasites by Human Factor Hegress from the enveloping host erythrocyte. Within approxi-
mately 20 min after the blood meal, the fertile gametes have
formed, and fertilization occurs within 1 hr post-blood meal.
Following fertilization, the zygote transforms within one day
into a motile ookinete, which is able to exit the midgut lumen
(reviewed in Pradel, 2007).
A first attempt to investigate the influence of host complement
factors on the sexual stages of malaria parasites was undertaken
by Grotendorst and colleagues in 1986. Using the chicken ma-
laria model, the authors showed that P. gallinaceum zygotes
were sensitive to the APC in active serum, while heat-inactivated
serum had no effect on the parasites (Grotendorst et al., 1986).
The zygotes evaded APC lysis by binding to an (unidentified)
trypsin- and heat-sensitive component of the blood meal, but
the parasites lost their protection at 6–8 hr post-bloodmeal (Gro-
tendorst and Carter, 1987). Margos et al. (2001) confirmed these
results in the rodent malaria parasite P. berghei. While rat APC
factors were present in the mosquito midgut for several hours
following the blood meal, the sexual-stage parasites were pro-
tected from complement-induced lysis for approximately 3 hr.
The authors hypothesized that the sexual stages utilize the
GPI-anchored protectin CD59, a regulator protein of human
cell surfaces, to protect from human complement. However,
no incorporated CD59 was detected on the parasite surface
(Margos et al., 2001). The factor, which protects malaria para-
sites from APC, therefore remained unknown.
RESULTS
The APC of the Mosquito Blood Meal Interferes
with Gametogenesis of P. falciparum
We determined the concentration of C3a as a marker for APC
activation in Anopheles stephensi midguts between 5 min and
20 hr postfeeding via ELISA. The C3a concentration was
2.3-fold higher in blood meal samples at 1 hr post-blood meal
compared to PBS control (Figure 1A, left). Subsequently, the
amount of C3a slowly decreased between 1 hr and 6 hr post-
blood meal until it reached control levels (Figure 1A, left).
In order to investigate the effect of midgut microbiota on APC
activity, we supplemented the sugarmeal of themosquitoes with
gentamicin. In the blood meal samples, a 3.2-fold increase in
C3a at 1 hr post-blood meal and a 2.1-fold C3a increase at
3–6 hr post-blood meal compared to PBS control was detected
(Figure 1A, right). Thus, human APC is active in the blood meal
during the first hour postfeeding, particularly in the absence
of midgut microbiota, since these appear to support APC inacti-
vation. After 3–6 hr postfeeding, the complement activity
decreased rapidly.
We then investigated parasite binding by complement factor
C1q, which is a marker for the antibody-mediated classical(C) Binding of FH to sexual-stage parasites after GC activation with NHS, HIS,
polyclonal anti-CCP1–CCP20 antiserum to visualize bound FH (155 kDa). Noninf
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(negative control). Immunoblotting with polyclonal anti-CCP1–CCP20 antiserum
Figure S1.
Cell Hpathway. P. falciparum GCs were activated in vitro at room
temperature (RT) using complement-active normal human
serum (NHS) either in the presence or absence of monoclonal
antibodies (mAbs) against the sexual-stage surface protein
Pfs230, which was previously shown to promote complement-
mediated lysis of gametes (e.g., Healer et al., 1997). Immuno-
blotting with anti-C1q antibodies revealed a minor binding of
C1q to the GCs at 15 min and 1 hr postactivation (p.a.) in the
absence of anti-Pfs230 mAbs, while C1q binding was increased
when GCs were activated in the presence of anti-Pfs230 mAbs
(Figure S1A). Immunoblotting with antiserum against the GC
protein PfCCp2 was used as a loading control (Figure S1B).
These data indicate that the activity of the classical pathway of
complement is low in the midgut of mosquitoes when these
were fed on the blood of naive individuals, but that the classical
pathway is activated in the presence of sexual stage-specific
antibodies.
After showing that the human complement is active in the
mosquito midgut for approximately 1 hr, we investigated how
the APCmight affect parasite sexual reproduction. We activated
mature GCs in vitro in the presence of NHS or heat-inactivated
human serum (HIS) and counted the number of exflagellation
centers (an indicator of activated male GCs), macrogametes,
and zygotes at 15 min, 20 min, and 20 hr p.a., respectively.
In HIS-activated GC cultures, the numbers of exflagellation
centers, macrogametes, and zygotes were significantly higher
than in cultures that were activated in the presence of NHS
(Figure 1B), indicating that active human complement impairs
gametogenesis.
We then investigated if FH is used by the extracellular sexual-
stage parasites for protection against human complement.
Therefore, mAbs against FH (mAb clone 131X directed against
CCP8–CCP15; see Figure S1C), which functionally inactivate
FH (Oppermann et al., 2006), were added to the activated GC
cultures. The presence of anti-FH mAbs significantly reduced
the numbers of macrogametes and zygotes and further reduced
the number of exflagellation centers compared to NHS-treated
controls without anti-FH antibody (Figure 1B). The data indicate
that the functional inactivation of FH results in an increased lysis
of the extracellular sexual stages by the APC. In HIS-activated
GC cultures, the presence of anti-FH mAbs had no influence
on the number of sexual-stage parasites (Figure 1B).
FH Binds to the Surface of Macrogametes and Young
Zygotes
To investigate if the sexual-stage parasites are able to bind
FH, mature GCs were activated with NHS and subjected to
indirect immunofluorescence assays (IFAs) between 15 min
and 20 hr p.a. using polyclonal anti-CCP1–CCP20 antiserum
(see Figure S1C). While erythrocytes and the nonactivatedor SAX in the absence or presence of FH, as shown by immunoblotting with
ected erythrocytes (EC) were used for negative control.
ith NHS, as shown by immunoblotting with polyclonal anti-CCP1–CCP20 anti-
R-1b (36 kDa). NHS and S. aureus strain Newman served as a positive control.
ng sites for C3b and heparin (Hep) are indicated.
n with SAX supplemented with recombinant FH deletion mutants or CFHR-1
detected binding of peptide CCP1–CCP7 (equal to FHL-1; 40 kDa). See also
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Figure 2. Binding of FH and C3b to Sexual-Stage Parasites
(A) Binding of FH to sexual-stage parasites after GC activation with NHS, as shown by IFA, using polyclonal anti-CCP1–CCP20 antiserum to detect FH (green).
The sexual stages were labeled with antibodies against the respective marker proteins (PfCCp4, GCs; Pfs230, macrogametes [MaGs]; Pfs25, young zygotes;
Pfs28, old zygotes; red), noninfected red blood cells (RBCs) were labeled with Evans Blue (EB, red). Bar, 5 mm.
(B) For negative control, Kluyveromyces lactis was incubated with 500 mg/ml of FH for 1 hr. No FH binding (green) was detected via IFA using anti-CCP1–CCP20
antiserum. The yeast were counterstained with Evans Blue (red). Bar, 5 mm.
(C) Binding of C3b to sexual-stage parasites after GC activation with NHS. The IFA was pursued as described in (A). C3b was detected using a polyclonal anti-C3
antibody (green). Bar, 5 mm. See also Figure S2.
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Protection of Malaria Parasites by Human Factor Hintraerythrocytic GCs exhibited a low FH labeling on their
surfaces, which is due to the permanent binding of FH to body
cells (Figure 2A), emerging macrogametes and young zygotes
showed an enhanced labeling for FH on their surfaces when
being investigated at time points between 15 min and 3 hr p.a.
FH labeling decreased at 20 hr p.a. (Figure 2A). For negative
control, we used Kluyveromyces lactis (kindly provided by U.
Commandeur, RWTH Aachen University, Germany), which did
not label for FH (Figure 2B).
We also investigated the binding of FH to the surface of acti-
vated GCs by western blotting (WB). GCs were activated by
either NHS or the gametogenesis-inducing activation medium
SAX, which was supplemented with purified FH at a concentra-
tion of 500 mg/ml (as found in plasma). Samples were taken at six
different time points between 10 min and 6 hr p.a. and immuno-
blotted with anti-CCP1–CCP20 antisera. For all time points,
prominent FH bands of approximately 155 kDa were detected
in the GC samples activated by NHS (Figure 1C, top left) or by32 Cell Host & Microbe 13, 29–41, January 16, 2013 ª2013 Elsevier IFH-supplemented SAX (Figure 1C, bottom left). The FH bands
of these samples were more intense than the respective bands
of noninfected erythrocytes, which were used as a negative
control. When GCs were activated with HIS or SAX, FH labeling
was low (Figure 1C, right panel). The combined data show that
active FH strongly binds to the surface of the in vitro cultivated
gametes and young zygotes of P. falciparum for a time period
of at least 6 hr.
Sexual-Stage Parasites Bind FH and FHL-1, but Not
CFHR-1
Besides FH, two additional regulatory proteins were previously
shown to be bound by human pathogens for immune evasion:
FHL-1 and CFHR-1 (reviewed in Zipfel et al., 2007). We therefore
investigated if these proteins are also recruited by Plasmodium
parasites. In NHS, immunoblotting with anti-CCP1–CCP20 anti-
serum detected a protein band corresponding to the FHL-1
protein (37 kDa) the two differently glycosylated chains ofnc.
Cell Host & Microbe
Protection of Malaria Parasites by Human Factor HCFHR-1, termed CFHR-1a and CFHR-1b (34 and 36 kDa,
respectively), and the 155 kDa protein band of FH (Figure 1D,
left). When NHS-activated GCs were immunoblotted between
30 min and 20 hr p.a., a prominent FH signal as well as a faint
protein band for FHL-1, but no CFHR-1 signal, was detected
(Figure 1D, left). When lysates of Staphylococcus aureus strain
Newman (kindly provided by K. Ohlsen, University of Wu¨rzburg,
Germany), used as positive control, were incubated with NHS
and immunoblotted with anti-CCP1–CCP20 antiserum, protein
bands for FH, FHL-1, CFHR-1a, and CFHR-1b were detected
(Figure 1D, right).
Additional binding assays were performed using three anti-FH
antibodies, i.e., mAb C18 directed against CCP18–CCP20, mAb
131X, and a polyclonal antiserum directed against CCP1–CCP4,
in addition to the previously used polyclonal anti-CCP1–CCP20
antiserum (Figure S1C). While mAb C18 only detects FH and
CFHR-1 in NHS, the polyclonal anti-CCP1–CCP4 antiserum
detects FH and FHL-1, but not CFHR-1 (Figure S1D). Further,
antibody mAb 131X detects FH, but not the FH-related proteins.
These antibodies were used for probing the lysates of activated
GCs (15 min and 1 hr p.a.). All antibodies detected bound FH.
Furthermore, FHL-1 was detected on the parasite surface
when lysates were immunoblotted with the anti-CCP1–CCP4
or anti-CCP1–CCP20 antisera, while mAb C18 detected FH,
but not CFHR-1 (Figure S1E). These data underline that both
FH and FHL-1, but not CFHR-1, bind to the sexual-stage surface.
We then investigated at which time point FH becomes
degraded in the mosquito blood meal. Midguts of female
mosquitoes fed on human blood with and without malaria para-
sites were dissected between 0 min and 20 hr postfeeding and
subjected to WB using anti-CCP1–CCP20 antiserum. Both
experimental approaches showed that FH and FHL-1 were
stable in the mosquito midgut for approximately 6 hr (Figure S2).
Over time, a degradation product with a molecular weight of
approximately 120 kDa accumulated in the samples. Protein
bands for CFHR-1a and CFHR-1b were not detected, suggest-
ing that in themosquitomidgut CFHR-1 is immediately absorbed
or degraded. The combined data indicate that FH and FHL-1 are
stable in the mosquito midgut for approximately 6 hr, thus for as
long as it can be detected on the sexual-stage surface (compare
with Figure 2A).
Binding of FH to the Sexual-Stage Parasite Surface Is
Mediated by CCP Modules 5–7
In order to determine which of the 20 CCP modules were
primarily involved in binding to the parasite surface, eight re-
combinant FH deletion mutants, comprising different CCP
modules, were investigated. As a negative control, we tested re-
combinant CFHR-1. GCs were activated in vitro at RT for 45 min
using SAX medium, which was supplemented with a 100 ng/ml
concentration of one of the recombinant FH deletion mutants
per sample. The GC lysates were then immunoblotted with
anti-CCP1–CCP20 antiserum. Aprotein band running at amolec-
ular weight of approximately 40 kDawas detected, which resem-
bled the deletion mutant CCP1–CCP7 (Figure 1F). For none of
the other FH peptides were protein bands detected, including
deletion mutant CCP1–CCP4. CCP1–CCP7 was subsequently
tested in a concentration of 10 ng/ml, and again, a prominent
protein band was detected (Figure 1F, right lane). The combinedCell Hdata let us conclude that CCP modules 5–7 mediate binding of
FH and FHL-1 to the sexual-stage surface.
FH Binding to the Sexual-Stage Parasite Surface
Mediates C3b Inactivation
FH regulates the APC activity by supporting factor I-mediated
conversion of surface-associated C3b into iC3b following the
hydrolysis of C3 into C3a and C3b. FH binds to C3b and medi-
ates the proteolytic cleavage of the a0 chain of C3b by factor I,
eventually resulting in the fragments a01 and a02 and the b chain
(Figure 3A). First, we investigated the presence of C3b on the
parasite surface by IFA using anti-C3 antibody. While erythro-
cytes and nonactivated intraerythrocytic GCs exhibited a fine
C3b labeling on their surfaces, due to the permanent inactivation
of C3b on the surface of body cells, emerging macrogametes
showed an intense C3b-labeling between 15 and 30 min p.a.
(Figure 2C). We therefore conclude that C3b is present on the
gamete surface during the same time period FH is bound by
the parasite.
We then investigated via cofactor assay if the surface-bound
C3b is inactivated by FH and factor I. GCs were activated with
SAX medium in the presence or absence of purified FH. At
30 min p.a., purified C3b and factor I were added, and the
cultures were incubated for another 30 min at RT. Immunoblot-
ting with anti-C3 antibody showed that in the presence of FH,
the a0 chain of C3b was processed by factor I, and the peptides
a01 and a02 (67 and 40 kDa, respectively) appeared in addition to
the protein bands of a0 and b (101 and 75 kDa, respectively). In
GC samples without FH, however, the a0 chain was not cleaved
to a01 and a02 by factor I (Figure 3B).
We also observed C3b processing over time. GCs were acti-
vated in vitro at RT in the presence of NHS, and samples were
taken at 15 min and 1 hr p.a. GC lysates were immunoblotted
with anti-C3 antibodies. In activated GCs, the a01 and a02
peptides were detected, and these signals were more intense
than in the nonactivated GC control. Further, the signals for a01
and a02 slightly increased at 1 hr p.a. (Figure 3C).
Several C3b binding sites were previously identified within FH,
namely CCP1–CCP4, CCP12–CCP14, and CCP19–CCP20 (see
Figure 1E; Ku¨hn et al., 1995; Jokiranta et al., 1996, 2000). For
the latter two C3b-binding sites and for module CCP7 heparin
binding was described (Ku¨hn et al., 1995; Blackmore et al.,
1998; Prodinger et al., 1998; Weismann et al., 2011). We investi-
gated the C3b interaction with FH on the parasite surface via
competition studies. GCs were activated for 1 hr in NHS in the
presence or absence of heparin (5 mg/ml). Subsequently, the
GC lysates were immunoblotted with anti-C3 antibody. In
samples from GCs that were activated in the presence of
heparin, the signals for the C3b cleavage products a01 and a02
were lower as compared to GCs activated in the absence of
heparin (Figure 3D). These results indicate that heparin blocked
the C3b binding sites of FH, resulting in less C3b inactivation. As
a slightly reduced signal of the b chain was also detected in
samples of heparin-treated activated GCs, heparin might also
affect the overall binding of C3b to the parasite surface
(Figure 3D).
WBwas carried out to investigate if binding of heparin to CCP7
would decrease FH binding to the parasite surface, using the
above described experimental setting. Immunoblotting of GCsost & Microbe 13, 29–41, January 16, 2013 ª2013 Elsevier Inc. 33
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Figure 3. C3b Inactivation by FH Bound to
the Sexual-Stage Surface
(A) Schematic depicting the composition of C3b.
The cleavage sites are indicated.
(B) FH-mediated processing of C3b by factor I on
the sexual-stage surface after GC activation with
SAX in the presence or absence of FH, as shown
by immunoblotting with anti-C3 antibodies to
visualize bound C3b products a0 (101 kDa) and
b (75 kDa) and the processing products a01
(67 kDa) and a02 (40 kDa).
(C) C3b processing over time on the sexual-stage
surface after GC activation with NHS, as shown by
immunoblotting with anti-C3 antibodies to visu-
alize the C3b processing products. The a chain
signal originated from nonhydrolysed C3. For
negative control, GCs were kept in NHS at 37C;
for positive control, S. aureus strain Newman was
kept in NHS at 37C. Immunoblotting of purified
C3b highlighted the unprocessed a0 chain and the
b chain.
(D) C3b inactivation on the sexual-stage surface
after GC activation with NHS in the presence or
absence of heparin, as shown by immunoblotting
with anti-C3 antibodies to visualize the C3b pro-
cessing products. GCs activated in SAX were
used for negative control.
(E) FH binding to the sexual-stage surface after GC
activation with NHS in the presence or absence of
heparin, as shown by immunoblotting with anti-
CCP1–CCP20 antiserum (top). The signal strength
for the FH bands (arrow) was measured using the
ImageJ program (bottom). The results of three
independent experimentswere combined, and the
FH signal in GCs at 15 min p.a. was set to 100%
(represented as mean ± SD).
(F) For loading control, GCs were processed as
described in (E) and immunoblotted with anti-
PfCCp2 antiserum to detect PfCCp2 (185 kDa;
top, arrow). The signal strength was measured as
described in (E) (bottom).
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antiserum, showed a reduced FH binding by 41% (at 150 p.a.)
and 66% (at 1 hr p.a.) as compared to GCs activated in the34 Cell Host & Microbe 13, 29–41, January 16, 2013 ª2013 Elsevier Inc.absence of heparin (Figure 3E). Anti-
PfCCp2 antiserum was used for loading
control, and signal-strength quantifica-
tion did not reveal any differences in
PfCCp2 abundance between the dif-
ferent experimental settings (Figure 3F).
The combined data demonstrate that
FH binding to the parasite surface
involves the heparin binding site of
CCP7 and results in C3b inactivation.
Mass Spectrometry Identifies
Plasmodial PfGAP50 as FH-Binding
Protein
To identify the plasmodial FH receptor,
GCs were activated by NHS for 30 min,
and coimmunoprecipitation assays wereperformed using anti-FH mAb 131X bound to protein G beads.
As a negative control, the same assay was carried out with
asexual blood stages. The precipitated proteins were separated
A B
C
Figure 4. Identification of PfGAP50 as FH Receptor
(A) Mass spectrometric identification of PfGAP50 as FH receptor in GCs at
30min p.a. with NHS, following coimmunoprecipitation with anti-FHmAb 131X
and silver staining of SDS-PAGE (left, arrow). NHS-incubated mixed asexual
cultures were used for negative control. Immunoblotting with mouse poly-
clonal anti-PfGAP50 antiserum confirmed PfGAP50 in the immunoprecipitated
activated GC sample (right, arrow).
(B) Schematic depicting PfGAP50. SP, signal peptide; TM, transmembrane
domain.
(C) PfGAP50 expression in synchronized blood-stage schizonts, mature GCs,
and GCs at 1 hr p.a. as shown by immunoblotting with anti-PfGAP50 anti-
serum. PfGAP50 was running at a molecular weight of 45 kDa in the schizonts
lysate, and as a 45/42 kDa doublet in the GC lysates. See also Figure S3.
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a protein band in theGC sample, runningwith amolecular weight
of approximately 45 kDa, which was picked and subjected to
mass spectrometric analysis (Figure 4A, left). The detected
peptides were used for MASCOT searches to identify full-length
proteins (Figure S3). Mass spectrometry identified the 45 kDa
protein as the glideosome-associated protein GAP50 (Plas-
moDB gene ID: PF3D7_0918000).
A polyclonal mouse antiserum against the bacterially ex-
pressed PfGAP50 was generated, and immunoblotting detected
a similar protein band at 45 kDa in the immunoprecipitated GC
protein sample, but not in the asexual blood-stage protein
sample (Figure 4A, right), confirming that the identified protein
was PfGAP50.
PfGAP50 Relocates from the IMC to the Plasma
Membrane during GC Activation
PfGAP50 possesses an N-terminal and a C-terminal trans-
membrane domain and a signal peptide, as well as an atypical
metallo-dependent phosphatase domain (Figure 4B), as was
recently demonstrated by crystal structure analysis (Bosch
et al., 2012). PfGAP50 was originally assigned to the actin-
myosin motor complex of the parasite invasive stages, which is
part of the inner membrane complex (IMC) (Baum et al., 2006;
Sanders et al., 2007; Fre´nal et al., 2010; Yeoman et al., 2011).
We initially investigated the presence of PfGAP50 in blood-stage
parasites via WB using anti-PfGAP50 antiserum. In schizonts,
a single protein band of 45 kDa was detected (Figure 4C). In
mature GCs and GCs at 1 hr p.a., a protein doublet running at
approximately 45 and 42 kDa, respectively, was identified (Fig-
ure 4C), suggesting that in these stages a processed form of
PfGAP50 might be present.
PfGAP50 expression was further investigated by IFA. First,
cultures of asexual blood stages and of nonactivated GCsCell Hwere fixed with methanol (MeOH) and treated with a saponin
solution for membrane permeabilization in order to detect
both extracellular and intracellular PfGAP50. IFAs revealed an
abundant expression of PfGAP50 in the asexual blood stage
parasites, particularly in schizonts. Furthermore, PfGAP50 ex-
pression was detected in GCs (Figure 5A).
GCs exhibit a subpellicular membrane, which is ultrastructur-
ally identical with the IMC of the parasite invasive stages
(Figure S4A, left; Sinden, 1982) and which disintegrates approx-
imately 15 min following GC activation (Figure S4A, right; Solo-
gub et al., 2011). We wanted to confirm that the GC subpellicular
membrane is a typical IMC. First we compared the presence of
transcripts of typical IMC components between GCs and
asexual blood-stage parasites of the GC-less strain F12.
Diagnostic RT-PCR revealed the presence of transcripts for
pfgap45 and pfgap50, pfmtip, and aldolase, as well as of
actin I and actin II in GCs.While in asexual blood-stage parasites,
myosin isoforms A, B, and E predominate, transcripts formyosin
isoforms A, B, C, D, and F were detected in GC samples (Fig-
ure S4B). Subsequent IFAs confirmed the presence of actin I,
actin II, alpha-tubulin, and alpha-tubulin II and indicated the
presence of myosin (detected by anti-human myosin 1C anti-
body) in addition to PfGAP50 in the GCs (Figure S4C). These
data confirm the presence of a typical IMC in GCs and are in
accordance with recent findings by others (Dearnley et al.,
2012; Kono et al., 2012).
We subsequently investigated if PfGAP50 is present on the
surface of the emerging gametes and thus accessible to FH.
GC cultures were activated and fixed with paraformaldehyde
(PFA) in suspension at 15 min p.a. IFAs were performed in the
absence of saponin to ensure that only the extracellular proteins
would be detected; they revealed that PfGAP50 was present on
the macrogamete surface. Intraerythrocytic GCs, on the other
hand, did not label for PfGAP50, since the enveloping mem-
branes were not permeable for the antibodies (Figure 5B).
Similarly, when activated GC cultures were fixed with MeOH,
omitting saponin treatment, the macrogametes labeled for
PfGAP50 (Figure S5A). As a negative control, IFAs were per-
formed using an antiserum directed against proteasome subunit
alpha 5 (SU a5), and no labeling of macrogametes was detected.
In contrast, when parasites were permeabilized with saponin
before incubation with the anti-SU a5 antiserum, the macroga-
metes showed a signal for SU a5 (Figure S5A).
The question remained: in nonactivated GCs, was PfGAP50
associated with the IMC components or the plasmalemma?
We established a method in which live GCs were stripped of
their enveloping membranes by mild saponin treatment (0.05%
saponin for 8 min). Electron microscopy on stripped GCs re-
vealed that these were liberated from the host erythrocyte, while
nontreated GCs were harbored by an intact erythrocyte (Fig-
ure S5B). The stripped GCs were viable and could be activated
to undergo gametogenesis, as shown by in vitro exflagellation
assays (Figure S5C).
The stripped GCs were fixed with PFA and used in IFAs
without further membrane permeabilization. PfGAP50 was not
detectable on the surface of the stripped, nonpermeabilized
GCs, while in nonstripped, permeabilized GCs, PfGAP50 was
detected (Figure 5C). Similarly, no labeling was detected in the
stripped GCs when anti-human myosin 1C antibody was usedost & Microbe 13, 29–41, January 16, 2013 ª2013 Elsevier Inc. 35
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Figure 6. Binding of FH by PfGAP50
(A) Concentration-dependent binding of recombi-
nant CCP1–CCP20 (equal to FH), CCP1–CCP7
(equal to FHL-1), and CCP1–CCP4 to recombinant
immobilized PfGAP50. FH peptide binding was
measured colorimetrically at an optical density of
450 nm (represented as mean ± SD). Immobilized
gelatine and PBS alone were used for negative
controls. Significant differences in protein binding
are indicated (*p < 0.05, **p < 0.01, ***p < 0.001;
Student’s t test). ns, not significant.
(B) FH binding to sexual-stage parasites, following
GC activation with XA in the presence of 10% (v/v)
rabbit anti-PfGAP50 or anti-plasmepsin II antibody,
as shown by immunoblotting with anti-CCP1–
CCP20 antiserum (top). The signal strength for the
FH protein bands (arrow) was measured using the
ImageJ program (bottom). The results of two
independent experiments were combined, and the
FH signal in GC samples treated with anti-plas-
mepsin II antibody was set to 100% (represented
as mean ± SD).
(C) Lysis of stripped nonactivated GCs by
complement during incubation with NHS, as shown
by immunoblotting with antiserum against Pf39
(arrow) to demonstrate cell integrity. Nonstripped
GCs were used for control.
(D) Numbers of zygotes at 16 hr p.a. after GC
activation with XA in the presence of 20% (v/v)
rabbit anti-PfGAP50 or anti-plasmepsin II antibody.
The mean number of zygotes in the samples
treated with anti-plasmepsin II antibody was set to
100% (represented as mean ± SD). Significant
differences in zygote numbers are indicated (**p <
0.01; Student’s t test). See Also Figure S5.
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were positive for myosin. For a positive control, the stripped
GCs were incubated with antibodies against Pfs230, which is
present at the GC plasma membrane. Pfs230 labeling was de-
tected in the stripped, as well as the membrane-permeabilized,
GCs (Figure 5C).
We also investigated by IFA how long PfGAP50 is present on
the sexual-stage surface following GC activation. PfGAP50
was present in activated GCs and macrogametes between
15 min and 6 hr p.a. (Figure 5D). The combined data indicate
that in GCs, PfGAP50 is part of the IMC, but that the protein is
relocated to the parasite surface during GC activation.
Plasmodial PfGAP50 Binds FH on the Parasite Surface
Protein-protein binding assays were employed to determine if
PfGAP50 is able to directly bind FH and FHL-1. RecombinantFigure 5. Localization of PfGAP50 in the Blood- and Sexual-Stage Par
(A) PfGAP50 expression in blood-stage parasites as shown by IFA following MeO
anti-PfGAP50 antiserum (green), asexual blood-stage parasites were highlighte
bodies (red). Nuclei were highlighted with Hoechst nuclear stain (blue). DIC, diffe
(B) Surface-associated expression of PfGAP50 in emergedmacrogametes, follow
was pursued as described in (A). Arrowhead indicates nonactivated GC. Bar, 5 m
(C) Subcellular localization of PfGAP50 in nonactivatedGCs, following stripping by
without further saponin permeabilization. Untreated GCs were fixed with MeOH
myosin 1C, or anti-Pfs230 antisera (green) and counterstained with Evans Blue (
(D) Expression of PfGAP50 in sexual-stage parasites. The parasites were fixed wit
and PfGAP50 (green). MaG, macrogamete. Bar, 5 mm. See also Figure S4.
Cell HPfGAP50 was immobilized to a microtiter plate and incubated
with recombinant FH (CCP1–CCP20) or FHL-1 (CCP1–CCP7)
at concentrations of 2.5, 5, or 10 mg/ml. The binding intensity
was colorimetrically evaluated. FH as well as FHL-1 bound to
PfGAP50 in a concentration-dependent manner (Figure 6A).
Interestingly, a fragment representing CCP1–CCP4 did not
bind to recombinant PfGAP50, thus confirming that binding of
FH to the parasite surface is preferentially mediated by CCP
modules 5–7 (Figure 6A).
The binding of FH to PfGAP50 was also investigated by quan-
titative WB. GCs were activated by xanthurenic acid (XA) in the
absence of NHS and in the presence of polyclonal rabbit anti-
PfGAP50 antiserum (kindly provided by Julian Rayner, Wellcome
Trust Sanger Institute, UK) or rabbit antibody directed against
the protease plasmepsin II, whichwas used as a negative control
(a 10% [v/v] concentration was used). At 15 min p.a., NHS wasasites
H fixation and saponin permeabilization. PfGAP50 was labeled with polyclonal
d with anti-MSP1 antibodies, and GCs were highlighted with anti-Pfs25 anti-
rential interference contrast. Bar, 5 mm.
ing PFA fixation at 30min p.a. without further saponin permeabilization. The IFA
m.
saponin treatment to remove the envelopingmembranes and after PFA fixation
and saponin permeabilized. GCs were labeled with anti-PfGAP50, anti-human
red). Bar, 2 mm.
hMeOH, saponin permeabilized, and labeled with antisera against Pfs230 (red)
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Table 1. Transmission Blocking Assays with Anti-FH, Anti-PfGAP50, and Control Antibodies
Transmission
Blocking Assay Feed
Infections/
Total (#)
Oocysts/Midgut
(mean ± SD), Range
Infection
Rate (%)
Reduction in
Transmission (%)
Experimental setting 1: a-FH
TBA 1 NHS 10/14 4 ± 4, 1–16 71 –
NHS + a-FH 0/14 0, N.A. 0 100
TBA 2 NHS 9/18 2 ± 2, 1–5 50 –
NHS + a-FH 0/9 0, N.A. 0 100
TBA 3 NHS 4/18 2 ± 1, 0–3 22 –
NHS + a-FH 0/18 0, N.A. 0 100
NHS + a-FGF 5/20 2 ± 1, 0–2 25 n.r.
TBA 4 NHS 11/20 3 ± 2, 0–7 55 –
NHS + a-FGF 12/20 5 ± 3, 0–11 60 n.r.
HIS + a-FH 9/20 2 ± 2, 0–8 45 18
TBA 5 NHS 9/20 3 ± 2, 0–7 45 –
NHS + a-FGF 10/20 3 ± 3, 0–9 50 n.r.
TBA 6 NHS 4/20 2 ± 1, 0–3 20 –
HIS + a-FH 5/20 2 ± 1, 0–3 25 n.r.
Experimental setting 2: a-PfGAP50
TBA 1 NMS 10/20 3 ± 3, 0–9 50 –
a-PfGAP50 6/20 2 ± 1, 0–2 30 40
TBA 2 NMS 8/17 1 ± 1, 0–3 47 –
a-PfGAP50 3/20 1 ± 1, 0–2 15 68
TBA 3 a-Pf39 8/20 2 ± 1, 0–4 40 –
a-PfGAP50 5/20 1 ± 1, 0–2 25 38
FGF, fibroblast growth factor (control mAb); N.A., not applicable; n.r., no reduction.
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another 15 min. The GC lysates were immunoblotted with anti-
CCP1–CCP20 antiserum, showing that antibody-mediated
blocking of PfGAP50 decreased FH binding by 61% as
compared to control GCs treated with anti-plasmepsin II anti-
body (Figure 6B).
If PfGAP50 represents the plasmodial FH receptor enabling
protection of the parasite from lysis by the human complement
and if PfGAP50 is not yet present on the surface of nonactivated
GCs, then these should, in consequence, be vulnerable to
human complement. In order to prove this hypothesis, mature
GCs were liberated from the enveloping membranes by saponin
stripping and incubated for 30 min in NHS at 37C (compare
Figures S5B and S5C). The cell pellets were immunoblotted
with antiserum against the intracellular endoplasmic reticulum-
associated protein Pf39. Samples of stripped GCs exhibited
only a very faint Pf39 signal when compared to control GCs
that were not stripped (Figure 6C). The decrease of the Pf39
signal demonstrates loss of cell integrity in the samples of strip-
ped GCs, indicating that these GCs were lysed by human
complement.
Subsequently, we investigated if the blockade of PfGAP50 on
the gamete surface by anti-PfGAP50 antibodies had an effect on
the development of midgut-specific stages. The numbers of
zygotes were determined in GC cultures at 16 hr p.a. in two inde-
pendent experiments. When rabbit anti-PfGAP50 antiserum was
added to the GC cultures before activation, the numbers of
zygotes were significantly decreased by 42% and 44%, respec-38 Cell Host & Microbe 13, 29–41, January 16, 2013 ª2013 Elsevier Itively, as compared to cultures supplemented with rabbit anti-
plasmepsin II antibodies (Figure 6D).
Impaired FH Function Results in Reduced Parasite
Transmission to the Mosquito
In a final set of experiments, we investigated if impaired FH func-
tion has an effect on the transmission of P. falciparum from the
human to the mosquito. First, the effect of antibody-mediated
FH inactivation during parasite transmission was determined
via ex vivo transmission blocking assays (TBAs). Female An. ste-
phensi mosquitoes were fed on mature GC cultures in the pres-
ence of NHS. In one experimental set up, anti-FH mAb 131X was
added at a concentration of 0.25 mg/ml (diluted in PBS) to the
GC culture, while in a second setup a similar volume of PBS
was added (termed NHS control). Three independent experi-
ments were performed, showing that the presence of anti-FH
mAbs resulted in a complete blockade (100% reduction) of para-
site transmission to the mosquito (Table 1). For negative
controls, mosquitoes were fed with cultures, to which similar
concentrations of mAbs directed against human fibroblast
growth factor (FGF) were added. Three independent feeds
were performed, showing that the presence of anti-FGF mAb
in the midgut did not decrease mosquito infections compared
to NHS control. As a second control, anti-FH mAbs were added
to GC cultures in the presence of HIS, and these were fed to
mosquitoes. Two independent feeds demonstrated that the
anti-FH mAb did not affect mosquito infection rates when the
complement was inactivated (Table 1).nc.
Cell Host & Microbe
Protection of Malaria Parasites by Human Factor HWe then investigated if the use of anti-PfGAP50 antiserum
would phenocopy the effect of the anti-FH mAbs in TBAs.
Female An. stephensi mosquitoes were fed on mature GC
cultures in the presence of neutral mouse serum (NMS), poly-
clonal mouse anti-PfGAP50 antiserum, or mouse anti-Pf39
antiserum, which was used as an additional negative control.
Three independent experiments were performed, showing that
the presence of anti-PfGAP50 antiserum reduced the transmis-
sion rates by 40%, 68%, and 38%, when compared to the
respective controls (Table 1).
In conclusion, the TBAs demonstrate that a loss of FH-
mediated protection, either by functionally inhibiting FH using
anti-FH antibodies or by blocking the FH receptor PfGAP50,
results in a significantly decreased transmission of Plasmodium
to the mosquito. Thus, in the absence of surface-bound protec-
tive FH, human complement clears the midgut parasites.
DISCUSSION
In this study, we identified the protective component that enables
APC evasion of the mosquito midgut stages of P. falciparum as
human FH. Emerging gametes and young zygotes bind FH, and
to a lower extend FHL-1, on their surface; in consequence,
surface-bound C3b becomes processed by factor I. We show
that FH is being slowly degraded in the midgut during a period
of 6 hr, while the human APC of the blood meal is active for
1–3 hr. Thus APC activity ceases before FH is degraded.
We recently showed that during gametogenesis the parasites
remain covered by the EM for approximately 15 min before the
membrane ruptures and releases the newly formed gametes
(Sologub et al., 2011). The prolonged stay of the emerging
gametes in the remnants of the host cell is probably a strategy
to hide from the APC during its most active phase, thus providing
the forming gametes with enough time to prepare for protection.
Subsequently, the gametes have to rapidly bind FH to avoid
complement-mediated lysis.
Both FH and FHL-1 bind to activated GCs, which is mediated
by CCP modules 5–7. Because FHL-1 is present in the blood in
a much lower concentration than FH (with a plasma concentra-
tion of 30 mg/ml for FHL-1 versus 500 mg/ml for FH; Zipfel and
Skerka, 1999, 2009; Rodrı´guez de Co´rdoba et al., 2004), malaria
parasites appear to preferentially co-opt FH for protection
against the human APC.
We identified the plasmodial transmembrane protein PfGAP50
as a receptor for FH and FHL-1. In accordance with previous
findings (Dearnley et al., 2012; Kono et al., 2012), we showed
that PfGAP50 is part of the IMC in GCs. After GC activation
and following disintegration of the IMC during gametogenesis,
though, PfGAP50 was detected on the macrogamete surface.
We hypothesize that during GC activation, PfGAP50 is being re-
located to the parasite plasmalemma, where it functions as an
FH receptor. The combined data show that PfGAP50 exhibits
multiple functions in the blood stages of malaria parasites and
further indicate that components of the IMC might be recycled
after IMC disintegration.
Antibodies against PfGAP50 are able to inhibit the binding of
FH to the sexual-stage surface. By blocking the FH receptor,
the sexual stages lose their ability to protect against human
complement and in consequence, anti-PfGAP50 antibodiesCell Hcause a reduction in the numbers of zygotes and also in the rate
of Plasmodium-infected mosquitoes. Because anti-PfGAP50
antibodies were not able to fully block parasite transmission to
the mosquito, we hypothesize that additional receptors for FH
binding are present on the sexual-stage surface, as has previ-
ously been shown for Candida albicans and Staphylococcus
aureus. Of note, these two pathogens additionally secrete
complement-binding proteins in order to inhibit the human
complement before this is able to bind to the pathogen surface
(Serruto et al., 2010; Luo et al., 2011). Considering the high
number of secreted sexual-stage specific adhesion proteins
(like Pfs230 or the LCCL-domain proteins; reviewed in Pradel,
2007) it remains to be elucidated if a similar mechanism is being
used by the plasmodial gametes for immune evasion in the
prefield.
Furthermore, mAbs directed against FH, when taken up with
the infected blood meal, are able to fully block transmission of
Plasmodium to the mosquitoes. While the functional inactivation
of FH in the presence of active serum results in an approximate
61% reduction of zygotes in the in vitro assays, FH inactivation
leads to a 100% reduction of mosquito infections in the ex vivo
assays. This discrepancy between the in vitro and ex vivo results
might be explained by additional factors that play a role during
mosquito infection. On the one hand, in the mosquito blood
meal lessGCs are present per volume than in the in vitro cultures,
and the partial elimination of gametes by human complement
might significantly decrease the chance of the parasite finding
amating partner. Other factors that pose a threat for the parasite,
and thus contribute to the bottleneck effect during the human-to-
mosquito transmission of malaria parasites, include the high
number of midgut bacteria as well as mosquito immune
response mechanisms, which affect both the bacteria and the
parasite (e.g., Dong et al., 2009; Meister et al., 2009).
In our study we revealed that FH binding to the sexual-stage
surface is essential for parasite survival in themidgut. The results
offer further approaches to block malaria transmission to the
mosquito. Importantly, antibodies directed against plasmodial
FH receptor proteins, like the here-described PfGAP50, are
able to functionally inhibit APC evasion. Receptor proteins
utilized by the malaria parasite for protection against the human
complement may represent ideal targets for transmission block-
ing vaccines.
EXPERIMENTAL PROCEDURES
Expression of Recombinant Proteins and Derivation of Mouse
Antisera
Recombinant proteins were expressed as GST-tagged fusion proteins in
E. coli BL21 (DE3) RIL cells (Stratagene), using the pGEX-4T-1 vector (Amer-
sham Biosciences). Immune sera against inclusion bodies were generated
by the immunization of 6-week-old female NMRI mice (Charles River Labora-
tories) with 100 mg recombinant protein emulsified in Freund’s incomplete
adjuvant (Sigma-Aldrich) followed by a boost after 4 weeks. Immune sera
were collected 10 days after the second immunization via heart puncture.
Housing and handling of the animals followed the guidelines of the animal
welfare committee of the government of Lower Franconia. Details are provided
in Supplemental Experimental Procedures.
Indirect Immunofluorescence Assay
P. falciparum NF54 parasite cultures were either air-dried on Teflon slides and
fixed in MeOH at 80C for 10 min or fixed in 4% PFA/PBS in suspension forost & Microbe 13, 29–41, January 16, 2013 ª2013 Elsevier Inc. 39
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Protection of Malaria Parasites by Human Factor H2 hr at 4C. The fixed cells were blocked in 3% BSA in PBS for 30 min. For
membrane permeabilization, fixed cells were incubated for 30 min in 0.01%
saponin/0.5% BSA/PBS. The specimens were incubated for 1.5 hr at 37C
with the primary antibody, followed by the fluorophore-conjugated secondary
antibody for 1 hr. Counterstaining was performed using 0.05% Evans Blue in
PBS (Sigma-Aldrich). Nuclei were highlighted by Hoechst 33342 (Invitrogen).
Labeled specimens were examined by immunofluorescence or confocal laser
scanning microscopy. Details are provided in Supplemental Experimental
Procedures.
Coimmunoprecipitation Assay
Parasites were incubated with 10 ml of RPMI incomplete medium containing
0.02% saponin for 5 min to remove the erythrocytes and lysed in 500 ml PBS
containing 0.5% saponin and 0.5% NP40. The lysate was sonicated for
1 min on ice. The supernatant was prepurified by incubation with 20 ml of
protein G beads (Santa Cruz Biotechnology) for 30 min at 4C and subse-
quently incubated for 1 hr at 4C with 2% (v/v) mAb 131X, followed by another
hour with 20 ml of protein G beads added. The beads were subjected to nonre-
ducing gel electrophoresis (NRGE) followed by mass spectrometry or WB.
Details are provided in Supplemental Experimental Procedures.
Western Blot Analysis
Parasite pellets were separated by SDS-PAGE or NRGE (in the case of FH
detection) and transferred to Hybond ECL nitrocellulose membrane (Amer-
sham Biosciences) according to the manufacturer’s instructions. Membranes
were blocked in Tris-buffered saline containing 5% skim milk and 1% BSA,
incubated for 2 hr at RT with the primary antibody, followed by another hour
at RT with an alkaline phosphatase-conjugated secondary antibody (Sigma-
Aldrich), and developed in a solution of nitroblue tetrazolium chloride (NBT)
and 5-brom-4-chlor-3-indoxylphosphate (BCIP; Sigma-Aldrich). Band intensi-
ties of scanned blots were measured by ImageJ version 1.44p (NIH). Details
are provided in Supplemental Experimental Procedures.
Complement Activity Assay
Female An. stephensimosquito midguts were dissected at eight different time
points between 5 min and 20 hr postfeeding in triplicate, and the C3a concen-
tration was measured by ELISA using the C3a Plus EIA Kit (Quidel). Details are
provided in Supplemental Experimental Procedures.
In Vitro Inhibition Assays
GCs were activated with 100 mMXA in NHS or HIS in the presence or absence
of 500 mg/ml of mAb 131X and incubated for 15 min, 20 min, or 20 hr at RT.
Subsequently, the exflagellation centers were counted under the microscope,
or the numbers of macrogametes (labeled by anti-Pfs25 antibodies) and
zygotes (labeled by anti-Pfs28 antibodies) were counted following IFA. The
experiments were performed in triplicate. Details are provided in Supplemental
Experimental Procedures.
GC-FH Deletion Mutants Binding Assay
GCs were activated at RT in SAX containing 100 ng/ml or 10 ng/ml of the re-
combinant FH deletion proteins. The erythrocytes were lysed with 1 ml of
RPMI incomplete medium containing 0.02% saponin for 5 min. The parasite
pellet was subjected to WB. Details are provided in Supplemental Experi-
mental Procedures.
Cofactor Assay
GCs were activated in 15 ml SAX in the presence or absence of 125 ng purified
FH for 30 min at RT. The activated GCs were incubated with 125 ng purified
C3b and 75 ng purified factor I for another 30 min at RT. The cells were incu-
bated with 1 ml of RPMI incomplete medium containing 0.02% saponin for
5 min. The cell pellet was subjected to WB. Details are provided in Supple-
mental Experimental Procedures.
PfGAP50-FH Binding Assay
Recombinant PfGAP50 or gelatine (10 mg/ml) were coated onto MaxiSorp
microtiter plates (Nunc) at 4C overnight and incubated with FH, CCP1–
CCP7, or CCP1–CCP4 (each 2.5, 5, or 10 mg/ml). Bound proteins were de-
tected with polyclonal FH antiserum (Complement Technology, Inc., Tyler,40 Cell Host & Microbe 13, 29–41, January 16, 2013 ª2013 Elsevier ITX) and secondary horseradish conjugated rabbit anti-goat antibody.
The reaction was developed with 1,2-phenylenediamine dihydrochloride
(DakoCytomation), and absorbance was measured at an optical density of
450 nm. Details are provided in Supplemental Experimental Procedures.
RNA Isolation and Transcript-Level Analysis
Parasite RNAwas isolated using the TRIzol reagent (Invitrogen) and cDNAwas
synthesized using the SuperScript II cDNA Synthesis Kit (Invitrogen). RT-PCR
assays were performed with 125 ng cDNA by conventional thermocycling
(25 cycles) using gene-specific primers (listed in Table S1). Samples lacking
reverse transcriptase were used for gDNA control. Details are provided in
Supplemental Experimental Procedures.
Electron Microscopy
NF54 GC cultures before and 15 min p.a. with XA were fixed in 1% glutaralde-
hyde and 4% PFA in PBS for 2 days and embedded in Epon. Details are
provided in Supplemental Experimental Procedures.
Zygote Development Assay
GCs were activated by 100 mM XA in NHS supplemented with 20% (v/v) of
rabbit anti-PfGAP50 or anti-plasmepsin II antibodies and incubated for 16 hr
at RT. Live zygotes were incubated with mouse anti-Pfs25 antibodies for
1 hr at RT followed by labeling with Alexa Fluor 488-conjugated goat anti-
mouse antibodies for 1 hr at RT. The numbers of zygotes were counted in
triplicate, using a hemocytometer. Details are provided in Supplemental
Experimental Procedures.
Transmission Blocking Assay
Percoll-purified GCs were mixed 1:1:1:1 with NHS, fresh human erythrocytes,
and PBS or mAbs at concentrations of 0.25 mg/ml. NHS was preincubated
with antibody or PBS in a 1:1 dilution for 30 min at RT. Mouse anti-PfGAP50
or anti-Pf39 antisera were tested at concentrations of 10% (v/v). Genta-
micin-treated 3- to 5-day-old female An. stephensi mosquitoes were fed for
20 min. At 10 days postfeeding, the mosquito midguts were dissected and
stained with 0.2% mercurochrome in PBS, and the numbers of oocysts per
midgut were counted under the microscope. Details are provided in Supple-
mental Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures, one table, and Supplemental
Experimental Procedures and can be found with this article online at http://
dx.doi.org/10.1016/j.chom.2012.11.013.
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